Abstract:Introduction The use of psychotropic medications has a notable effect on sexual well-being. Prolonged use is closely linked to dyspareunia, reduced sexual desire, hypogonadism, and erectile dysfunction. We hypothesized that there was an increase in the prescription rates of psychotropic medications among adolescent patients during the COVID-19 pandemic due to the unprecedented stress experienced by isolated youth. Objective We examined the prescription rates of psychotropic medications and the simultaneous usage of PDE5 inhibitors in adolescent patients during the COVID-19 pandemic in order to compare usage of these medications prior to the pandemic. Methods To conduct our retrospective matched cohort study, we utilized data obtained from the TriNetX Research Network. The study focused on adolescent patients aged 10-19 presenting for outpatient evaluation, and were placed into two cohorts: 1) those evaluated before the COVID-19 pandemic, and 2) those evaluated during the pandemic. Patients with previous psychiatric diagnoses or prior use of psychotropic medications were excluded from the study. Our primary interest was to examine new prescription patterns within 90 days of the outpatient evaluation. To ensure balanced cohorts, propensity score matching was conducted using logistic regression, resulting in cohorts of equal size. Results A total of 1,612,283 adolescents pre-COVID-19 and 1,008,161 adolescents presenting during the COVID-19 pandemic for outpatient evaluations were identified. After propensity matching, a total of 1,005,408 adolescents were included in each cohort each with an average age of 14.7 ± 2.84 and 52% female and 48% male. Prescribing of antipsychotics and benzodiazepines were more frequent during the pandemic for adolescents (RR: 1.58, 95% CI 1.01-2.2). However, they were less likely to receive antidepressants (Risk Ratio (RR): 0.6, 95% Confidence Interval (CI) 0.57-0.63), anxiolytics (RR: 0.78, 95% CI 0.75-0.81), stimulants (RR: 0.26, 95% CI 0.25-0.27), as well as mood stabilizers (RR: 0.44, 95% CI 0.39-0.49). Erectile dysfunction requiring oral PDE5i in this cohort was more frequent during the pandemic for adolescents (RR: 1.53, 95% CI 1.05-2.01). Conclusions During the global COVID-19 pandemic, there was a notable rise in the prescription rates of antipsychotic and benzodiazepine medications compared to previous years. Interestingly, this increase aligned with a statistically significant rise in the prescription of PDE5 inhibitors (PDE5i) for treating erectile dysfunction. These findings indicate that clinicians need to be aware of the potential increased risk of medication-related sexual dysfunction among adolescents. Disclosure Yes, this is sponsored by industry/sponsor: NIH health grant RO1 DK130991 and Clinician Scientist Development Grant from the American Cancer Society. Clarification: Industry funding only - investigator initiated and executed study.

The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946-1990

The construction of gender and mental health in Nordic psychotropic-drug advertising

Sex Differences in Pharmacotherapy of Schizophrenia:Findings from National Survey 2012 on Use of Psychotropic Medications

Direct-to-Consumer Advertising Survey of Psychiatrists in Massachusetts and Michigan

Sex Differences in Antidepressant Acceptability According to Filled Prescription Sequences in a Nationwide Cohort Study

Do antidepressant advertisements educate consumers and promote communication between patients with depression and their physicians?

The Psychopharmacological Thriller: Representations of Psychotropic Pills in American Popular Culture

[Antidepressants are frequently prescribed but still critized; a perspective on causes and solutions]

Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database

Deep pharma: psychiatry, anthropology, and pharmaceutical detox

Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency

Sexually Dimorphic Effects of Neuromodulatory Drugs on Normal and Stress-Induced Social Interaction in Rats

(319) Evaluating the Racial Distribution of Clinical Trial Participants for Drugs Leading to FDA Approval of Novel Biologics for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Maintaining a Fair Balance? Narrative and Non-Narrative Strategies in Televised Direct-to-Consumer Advertisements for Prescription Drugs Aired in the United States, 2003-2016

(127) Sexual Health Implications Associated with Psychotropic Medication Use Among Adolescents During the COVID-19 Pandemic

Gender inequalities in depression/anxiety and the consumption of psychotropic drugs: Are we medicalising women’s mental health?

Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: A systematic review

'At-risk' individuals' responses to direct to consumer advertising of prescription drugs: a nationally representative cross-sectional study

Trends of Polypharmacy and Prescription Patterns of Antidepressants in Asia

Sex differences in pharmacokinetics predict adverse drug reactions in women

The empowered patient on a historical-rhetorical model: 19th-century patent-medicine ads and the 21st-century health subject